U.S. markets closed
  • S&P Futures

    3,923.50
    +7.25 (+0.19%)
     
  • Dow Futures

    31,515.00
    +28.00 (+0.09%)
     
  • Nasdaq Futures

    12,190.50
    +50.00 (+0.41%)
     
  • Russell 2000 Futures

    1,764.30
    +2.60 (+0.15%)
     
  • Crude Oil

    107.84
    +0.22 (+0.20%)
     
  • Gold

    1,837.20
    +6.90 (+0.38%)
     
  • Silver

    21.36
    +0.24 (+1.11%)
     
  • EUR/USD

    1.0557
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2273
    +0.0003 (+0.03%)
     
  • USD/JPY

    134.7850
    -0.3850 (-0.28%)
     
  • BTC-USD

    21,142.66
    -219.38 (-1.03%)
     
  • CMC Crypto 200

    462.03
    +8.13 (+1.79%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,768.77
    +276.80 (+1.04%)
     

BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.

  • Annualized Bleeding Rate (ABR) was significantly reduced by 4.1 treated bleeds per year in the pre-specified primary analysis in participants from a prior non-interventional study.

  • Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII infusion rate in the rollover population by 133 infusions per year or 98% from baseline.

  • Related: Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit.

  • Overall, valoctocogene roxaparvovec has continued to be well tolerated.

  • No participants developed inhibitors to Factor VIII, malignancy, or thromboembolic events.

  • The European Medicines Agency validated BioMarin's resubmission of a marketing application. A Committee for Medicinal Products for Human Use and Committee for Advanced Therapies opinion is anticipated in 1H of 2022.

  • In the U.S., BioMarin intends to submit two-year follow-up safety and efficacy data GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, as previously requested by the FDA.

  • The Company plans to meet with FDA to discuss the resubmission of a marketing application targeted for Q2 2022, followed by an expected six-month review by the FDA.

  • Price Action: BMRN shares are down 1.17% at $84.25 during the premarket session on the last check Monday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.